NFKB1 and COVID-19: Accordingly, considering the COVID-19 pandemic, modifying a substantial nigra-related co-expression network by inhibiting TNF-α signaling via the NF-κB pathway, as the most significant upregulated pathway during PD, could also reduce COVID-19 symptoms in PD patients.